ISpecimen Inc ISPC is trading higher Thursday after the company announced the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research.
ISpecimen said the reference lab has the capacity to sequence hundreds of COVID-19 positive swabs per week. The lab is sequencing the most recent swabs in order to identify new variants of COVID-19 as the virus continues to progress.
"The sequencing of nasal swabs is necessary to determine which variant a patient has tested positive for and provides variant-positive specimens for research," said Christopher Ianelli, founder and CEO of ISpecimen.
ISpecimen announced it has delivered more than 15,000 specimens for more than 200 COVID-related projects since the start of the pandemic.
ISpecimen is a technology-driven company focused on connecting life science researchers who need human biofluids, tissues and living cells for their research, with the available biospecimens.
See Also: 20 Stocks Moving in Thursday's Pre-Market Session
ISPC Price Action: ISpecimen has traded as low as $4.75 and as high as $28.97 over a 52-week period.
The stock was up 12% at $7.65 at time of publication.
Photo: kkolosov from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
